On 1/6/25, VYNE Therapeutics Inc (NASDAQ: VYNE) stock enjoyed a major increase of 15.6%, closing at $4.00. Moreover, trading volume in this advance was exceptionally high at 269% of normal. Relative to the market the stock has been strong over the last nine months and has risen 23.8% during the last week.
Current PriceTarget Research Rating
VYNE Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. VYNE Therapeutics has a neutral Appreciation Score of 41 and a slightly positive Power Rating of 61, leading to the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment